<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">hfb</journal-id><journal-title-group><journal-title xml:lang="ru">Health, Food &amp; Biotechnology</journal-title><trans-title-group xml:lang="en"><trans-title>Health, Food &amp; Biotechnology</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2712-7648</issn><publisher><publisher-name>РОСБИОТЕХ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36107/hfb.2022.i4.s153</article-id><article-id custom-type="elpub" pub-id-type="custom">hfb-153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЗДОРОВЬЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>HEALTH</subject></subj-group></article-categories><title-group><article-title>Разработка технологии липосомной лекарственной формы циннаризина</article-title><trans-title-group xml:lang="en"><trans-title>Development of Cinnarizine Liposome Technology</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0123-9526</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полковникова</surname><given-names>Юлия Александровна</given-names></name><name name-style="western" xml:lang="en"><surname>Polkovnikova</surname><given-names>Yulia A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доцент кафедры фармацевтической химии и фармацевтической технологии</p></bio><email xlink:type="simple">juli-polk@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО "Воронежский государственный университет"</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Voronezh State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2022</year></pub-date><volume>4</volume><issue>4</issue><fpage>35</fpage><lpage>40</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Полковникова Ю.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Полковникова Ю.А.</copyright-holder><copyright-holder xml:lang="en">Polkovnikova Y.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.hfb-journal.ru/jour/article/view/153">https://www.hfb-journal.ru/jour/article/view/153</self-uri><abstract><sec><title>Введение</title><p>Введение. Липосомальные препараты обладают рядом преимуществ: защищают клетки организма от токсического действия лекарственных средств; пролонгируют действие введенного в организм лекарственного средства; защищают лекарственные вещества от деградации; способствуют проявлению нацеленной специфичности за счет селективного проникновения из крови в ткани; изменяют фармакокинетику лекарственных препаратов, повышая их фармакологическую эффективность; позволяют создать водорастворимую форму ряда лекарственных субстанций, увеличивая тем самым их биодоступность. В данной работе проведены исследования по разработке методики определения степени включения в липосомы из соевого лецитина циннаризина, нашедшего широкое применение как корректора нарушений мозгового кровообращения.</p></sec><sec><title>Цель</title><p>Цель. Цель исследования  - определить величины адсорбции циннаризина с липосомами из соевого лецитина.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Липосомы циннаризина из соевого лецитина получали методом гидратации/регидратации. Для изучения характеристик степени включения циннаризина в липосомы был использован метод равновесного диализа. Выбор данного метода обусловлен тем, что количественный анализ равновесной концентрации циннаризина в дисперсионной среде, необходимый для определения величины адсорбции, затруднен присутствием дисперсной фазы – липосом. Полупроницаемая мембрана, с диаметром пор, достаточным для проникновения молекул циннаризина, но не пропускающая липосомы, позволяет получить раствор циннаризина с концентрацией, достаточно близкой к концентрации в дисперсионной среде липосом. Получаемый таким образом раствор может быть подвергнут количественному анализу с использованием спектрофотометрии.</p></sec><sec><title>Результаты</title><p>Результаты. Построен график зависимости величины адсорбции циннаризина на липосомах от равновесной концентрации. Установлено, что величина адсорбции циннаризина при обработке липосом ультразвуком меньше для свех исследуемых концентраций.  При равновесной концентрации циннаризина более 0,0003 моль/л происходит стабилизация доли преарата связанного с липосомами. Без обработки ультразвуком на уровне 24,83 ± 1,15 %, с обработкой ультразвуком на уровне 18,4 ± 1,20 %.</p></sec><sec><title>Выводы</title><p>Выводы.  Установлено, что обработка липосом ультразвуком является целесообразной при добавлении циннаризина к сухой липидной плёнке, т.к. является фактором, повышающим биодоступность</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Liposomal preparations have a number of advantages: they protect the cells of the body from the toxic effects of drugs; prolong the action of the drug introduced into the body; protect medicinal substances from degradation; contribute to the manifestation of targeted specificity due to selective penetration from the blood into tissues; change the pharmacokinetics of drugs, increasing their pharmacological efficacy; allow you to create a water-soluble form of a number of medicinal substances, thereby increasing their bioavailability.</p><p>In this work, studies were carried out to develop a methodology for determining the degree of inclusion in liposomes from soy lecithin of cinnarizine, which has found wide application as a corrector of cerebral circulation disorders.</p></sec><sec><title>Purpose</title><p>Purpose. The purpose of the study is to determine the amount of adsorption of cinnarizine with liposomes from soy lecithin.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Cinnarizine liposomes from soy lecithin were prepared by the hydration/rehydration method. To study the characteristics of the degree of incorporation of cinnarizine into liposomes, the method of equilibrium dialysis was used. The choice of this method is due to the fact that the quantitative analysis of the equilibrium concentration of cinnarizine in the dispersion medium, which is necessary to determine the amount of adsorption, is hampered by the presence of a dispersed phase, liposomes. A semipermeable membrane with a pore diameter sufficient for the penetration of cinnarizine molecules, but impermeable to liposomes, makes it possible to obtain a cinnarizine solution with a concentration close enough to the concentration in the dispersion medium of liposomes. The solution thus obtained can be subjected to quantitative analysis using spectrophotometry.</p></sec><sec><title>Results</title><p>Results. A graph of the dependence of the value of adsorption of cinnarizine on liposomes on the equilibrium concentration was plotted. It was found that the value of adsorption of cinnarizine during the treatment of liposomes with ultrasound is less for all the studied concentrations. At an equilibrium concentration of cinnarizine of more than 0.0003 mol/l, the proportion of the prearat associated with liposomes stabilizes. Without sonication at the level of 24.83 ± 1.15%, with sonication at the level of 18.4 ± 1.20%.</p></sec><sec><title>Conclusion</title><p>Conclusion. It has been established that ultrasonic treatment of liposomes is expedient when cinnarizine is added to a dry lipid film, since it is a factor that increases bioavailability</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>липосомы</kwd><kwd>соевый лецитин</kwd><kwd>циннаризин</kwd><kwd>диализ</kwd><kwd>степень включения</kwd><kwd>ультразвук</kwd></kwd-group><kwd-group xml:lang="en"><kwd>liposomes</kwd><kwd>soy lecithin</kwd><kwd>cinnarizine</kwd><kwd>dialysis</kwd><kwd>inclusion degree</kwd><kwd>ultrasound</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">liposome: cinnarizine;  hydration/rehydration; calibration graph</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bertram L., Tanzi R.E. (2005) The genetic epidemiology of neurodegenerative disease. Journal of Clinical Investigation, 115(6), 1449–1457. https://doi.org/10.1172/JCI24761</mixed-citation><mixed-citation xml:lang="en">Bertram L., Tanzi R.E. (2005) The genetic epidemiology of neurodegenerative disease. Journal of Clinical Investigation, 115(6), 1449–1457. https://doi.org/10.1172/JCI24761</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Haress NG. Cinnarizine: Comprehensive Profile. Profiles Drug Subst Excip Relat Methodol. 2015;40:1-41. DOI: 10.1016/bs.podrm.2015.01.001.</mixed-citation><mixed-citation xml:lang="en">Haress NG. Cinnarizine: Comprehensive Profile. Profiles Drug Subst Excip Relat Methodol. 2015;40:1-41. DOI: 10.1016/bs.podrm.2015.01.001.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">DiSabella M.T. (2014) Cinnarizine: a promising agent for migraine prevention you may never get the chance to use. Pediatr Neurol., 51(4),475. doi:10.1016/j.pediatrneurol.2014.07.002.</mixed-citation><mixed-citation xml:lang="en">DiSabella M.T. (2014) Cinnarizine: a promising agent for migraine prevention you may never get the chance to use. Pediatr Neurol., 51(4),475. doi:10.1016/j.pediatrneurol.2014.07.002.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sethi S., Mangla B., Kamboj S., Rana V. (2018) A QbD approach for the fabrication of immediate and prolong buoyant cinnarizine tablet using polyacrylamide-g-corn fibre gum. Int J Biol Macromol., 117, 350-361. doi: 10.1016/j.ijbiomac.2018.05.178.</mixed-citation><mixed-citation xml:lang="en">Sethi S., Mangla B., Kamboj S., Rana V. (2018) A QbD approach for the fabrication of immediate and prolong buoyant cinnarizine tablet using polyacrylamide-g-corn fibre gum. Int J Biol Macromol., 117, 350-361. doi: 10.1016/j.ijbiomac.2018.05.178.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Maghsoodi M., Nokhodchi A., Oskuei M.A., Heidari S. (2019) Formulation of Cinnarizine for Stabilization of Its Physiologically Generated Supersaturation. AAPS PharmSciTech., 20(3), 139.</mixed-citation><mixed-citation xml:lang="en">Maghsoodi M., Nokhodchi A., Oskuei M.A., Heidari S. (2019) Formulation of Cinnarizine for Stabilization of Its Physiologically Generated Supersaturation. AAPS PharmSciTech., 20(3), 139.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Erdem S., Türkoğlu M. (2010) Glycyl-L-Histidyl-L-Liysine-Cu(2+) loaded liposome formulations. Marmara Pharm J., 14(2), 91-97. http://dx.doi: 10.12991/201014455</mixed-citation><mixed-citation xml:lang="en">Erdem S., Türkoğlu M. (2010) Glycyl-L-Histidyl-L-Liysine-Cu(2+) loaded liposome formulations. Marmara Pharm J., 14(2), 91-97. http://dx.doi: 10.12991/201014455</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Szoka F., Papahadjopoulos D. (1980) Comparative properties and methods of preparation of lipid vesicles (liposomes). Annual Review of Biophysics and Bioengineering, 9, 467–508. https://doi.org/10.1146/annurev.bb.09.060180.002343</mixed-citation><mixed-citation xml:lang="en">Szoka F.,  Papahadjopoulos D. (1980) Comparative properties and methods of preparation of lipid vesicles (liposomes). Annual Review of Biophysics and Bioengineering, 9, 467–508. https://doi.org/10.1146/annurev.bb.09.060180.002343</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Neuwelt E., Abbott N.J., Abrey L., Banks W.A., Blakley B., Davis T., Engelhardt B. (2008) Strategies to advance translational research into brain barriers. The Lancet Neurology, 7(1), 84–96. https://doi.org/10.1016/S1474-4422(07)70326-5</mixed-citation><mixed-citation xml:lang="en">Neuwelt E., Abbott N.J., Abrey L., Banks W.A., Blakley B., Davis T., Engelhardt B. (2008) Strategies to advance translational research into brain barriers. The Lancet Neurology,  7(1), 84–96. https://doi.org/10.1016/S1474-4422(07)70326-5</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Abbott N.J., Rönnbäck L., Hansson E. (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nature Reviews Neuroscience, 7(1), 41–53, 2006.</mixed-citation><mixed-citation xml:lang="en">Abbott N.J., Rönnbäck L., Hansson E. (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nature Reviews Neuroscience, 7(1), 41–53, 2006.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gregoriadis G. (2008) Liposome research in drug delivery: the early days. Journal of Drug Targeting. 16(7-8):520–524, 2008. https://doi.org/10.1038/nrn1824</mixed-citation><mixed-citation xml:lang="en">Gregoriadis G. (2008) Liposome research in drug delivery: the early days. Journal of Drug Targeting. 16(7-8):520–524, 2008. https://doi.org/10.1038/nrn1824</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Elbayoumi T.A., Torchilin V.P. (2010) Current trends in liposome research. Methods in Molecular Biology. 605:1–27. https://doi.org/10.1007/978-1-60327-360-2_1</mixed-citation><mixed-citation xml:lang="en">Elbayoumi T.A., Torchilin V.P. (2010) Current trends in liposome research. Methods in Molecular Biology. 605:1–27. https://doi.org/10.1007/978-1-60327-360-2_1</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lopalco A., Cutrignelli A., Denora N., Lopedota A., Franco M., Laquintana V. (2018) Transferrin Functionalized Liposomes Loading Dopamine HCl: Development and Permeability Studies across an In Vitro Model of Human Blood–Brain Barrier. Nanomater. 8(3): 178. http://doi.org/doi:10.3390/nano8030178.</mixed-citation><mixed-citation xml:lang="en">Lopalco A., Cutrignelli A., Denora N., Lopedota A., Franco M., Laquintana V. (2018) Transferrin Functionalized Liposomes Loading Dopamine HCl: Development and Permeability Studies across an In Vitro Model of Human Blood–Brain Barrier. Nanomater. 8(3): 178. http://doi.org/doi:10.3390/nano8030178.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Yalçın A.S., Türkoğlu M. (2010) Preparation of liposomes containing whey proteins. Marmara Med J., 23(1), 22-29.</mixed-citation><mixed-citation xml:lang="en">Yalçın A.S., Türkoğlu M. (2010) Preparation of liposomes  containing whey proteins. Marmara Med J., 23(1), 22-29.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Xiaoli L., Xiaoyong R., Jianmin L., Weijun M., Zhenghui W., Zhuangqun Y. (2017) Delivery of sodium morrhuate to hemangioma endothelial cells using immunoliposomes conjugated with anti-VEGFR2/KDR antibody. Int J Nanomedicine. 2017(12): 6963–6972. https://doi.org/10.2147/IJN.S144056</mixed-citation><mixed-citation xml:lang="en">Xiaoli L., Xiaoyong R., Jianmin L., Weijun M., Zhenghui W., Zhuangqun Y. (2017) Delivery of sodium morrhuate to hemangioma endothelial cells using immunoliposomes conjugated with anti-VEGFR2/KDR antibody. Int J Nanomedicine. 2017(12): 6963–6972. https://doi.org/10.2147/IJN.S144056</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Przewratil P., Sitkiewicz A., Wyka K., Andrzejewska E. (2009) Neuropilin-2 and vascular endothelial growth factor receptor-3 are up-regulated in human vascular malformations. Pediatr Dermatol. 26(4): 399–404. https://doi.org/10.1007/s10456-012-9305-x</mixed-citation><mixed-citation xml:lang="en">Przewratil P., Sitkiewicz A., Wyka K., Andrzejewska E. (2009) Neuropilin-2 and vascular endothelial growth factor receptor-3 are up-regulated in human vascular malformations. Pediatr Dermatol. 26(4): 399–404. https://doi.org/10.1007/s10456-012-9305-x</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Immordino M.L., Dosio F., Cattel L. (2006) Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 1: 297–315.</mixed-citation><mixed-citation xml:lang="en">Immordino  M.L.,  Dosio  F.,  Cattel  L.  (2006) Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 1: 297–315.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Spuch C., Navarro C. (2011) Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s disease and Parkinson’s Disease). J Drug Deliv., 2011(4), 1-12. http://dx.doi.org/10.1155/2011/469679.</mixed-citation><mixed-citation xml:lang="en">Spuch C., Navarro C. (2011) Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s disease and Parkinson’s Disease). J Drug Deliv., 2011(4), 1-12. http://dx.doi.org/10.1155/2011/469679.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
